You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 14, 2024

ALISKIREN HEMIFUMARATE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Aliskiren Hemifumarate, and when can generic versions of Aliskiren Hemifumarate launch?

Aliskiren Hemifumarate is a drug marketed by Endo Operations and is included in one NDA.

The generic ingredient in ALISKIREN HEMIFUMARATE is aliskiren hemifumarate. There are four drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the aliskiren hemifumarate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Aliskiren Hemifumarate

A generic version of ALISKIREN HEMIFUMARATE was approved as aliskiren hemifumarate by ENDO OPERATIONS on March 22nd, 2019.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ALISKIREN HEMIFUMARATE?
  • What are the global sales for ALISKIREN HEMIFUMARATE?
  • What is Average Wholesale Price for ALISKIREN HEMIFUMARATE?
Drug patent expirations by year for ALISKIREN HEMIFUMARATE
Pharmacology for ALISKIREN HEMIFUMARATE
Drug ClassRenin Inhibitor
Mechanism of ActionRenin Inhibitors
Paragraph IV (Patent) Challenges for ALISKIREN HEMIFUMARATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
TEKTURNA Tablets aliskiren hemifumarate 150 mg and 300 mg 021985 1 2014-01-27

US Patents and Regulatory Information for ALISKIREN HEMIFUMARATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo Operations ALISKIREN HEMIFUMARATE aliskiren hemifumarate TABLET;ORAL 206665-001 Mar 22, 2019 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Endo Operations ALISKIREN HEMIFUMARATE aliskiren hemifumarate TABLET;ORAL 206665-002 Mar 22, 2019 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.